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Abstract 
Triple-A Syndrome (TAS) is a rare autosomal recessive disorder characterized by three cardinal 
symptoms: alacrimia, achalasia and adrenal insufficiency due to ACTH insensitivity. Various 
progressive neurological abnormalities and skin changes have been described in association with the 
syndrome. The disease is caused by mutation in the AAAS gene on chromosome 12q13. Mutations 
in AAAS were identified in more than 90% of individuals and families with TAS. The protein encoded 
by AAAS was termed ALADIN and is part of the WD repeat family of proteins, that have been found to 
be involved in many different functions such as protein-protein interaction, RNA processing, 
cytoskeleton assembly, control of cell division, signal transduction and apoptosis. 
Immunohistochemical analysis showed that mutated or truncated ALADIN localizes to the cytoplasm 
rather than to the nuclear pore complex. The exact function of ALADIN and the mechanisms that lead 
to the ACTH-resistant adrenal phenotype remains largely unknown. Nonetheless, recent studies 
provided some insights on the role of ALADIN as a member of the Nuclear Pore Complex not only 
implicated in the import of proteins involved in DNA repair and oxidative stress homeostasis but also 
in the strengthening of the mitotic spindle assembly. Early identification of the syndrome is 
challenging, given the rarity of the condition and high phenotypic heterogeneity even among members 
of the same family. In this review, we aim to summarize the current knowledge of clinical and 
molecular profile of patients with TAS and recommendations for the diagnosis, management, and 
follow-up of patients. 
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Introduction 
Triple-A Syndrome (TAS) is a rare autosomic recessive disorder characterized by a highly 
heterogeneous phenotype, which is also known as Allgrove syndrome. Indeed, TAS was first 
discovered by Allgrove in 1978 1 who reported two pairs of siblings presenting the triad of symptoms 
of esophageal Achalasia, Adrenal insufficiency and Alacrimia. The disease was previously thought as 
belonging to the Familiar Glucorticoid Deficiency syndromes due to presence of adrenocorticotrophic 
insensitivity, although in the absence of any mutation of the ACTH receptor (also named MC2R). As a 
result of the combination of these three common manifestations the term Triple-A syndrome was then 
coined. TAS is a rare disease with a still unknown precise prevalence, mainly affecting inbred 
population, and with a variable phenotype of presentation. Due to its particular rarity, most of the 
current literature is represented by case reports. In the present review we aimed at extensively revising 
the known literature concerning the clinical and genetic clues of TAS. We thus provide the readers with 
an overview of the syndromic clinical features heterogeneity and we catalogue all known mutations, to 
report studies about the pathological mechanisms of AAAS gene mutations and ALADIN protein 
functions. 
Methods 
Pogliaghi et al, 2019
We performed literature search on PubMed for studies published up to November 2019 with the 
keywords “Triple-A Syndrome”, “Allgrove Syndrome”, “3A Syndrome”, “4A Syndrome”, “AAAS 
gene” and “ALADIN protein”. Meanwhile, we checked the references of each included paper to 
identify additional relevant publications.  
Inclusion Criteria for listing of mutations: 
1. Case reports, due to the rarity of the disease. 
2. Original articles and single center experiences with mutations reported. 
Exclusion Criteria for Studies: 
1. Absence of genotype analysis. 
Clinical presentation 
TAS is rather well known for its high heterogeneity in symptoms, and even subjects of the same family, 
harboring identical variants in the AAAS gene, can show a different degree of clinical manifestations, 
thus indicating a lack of genotype-phenotype correlation. The complete triad of Achalasia, Alacrimia 
and Adrenal Insufficiency (Allgrove triad) may not appear together at diagnosis and so the disease is 
sometimes named 2A syndrome. Moreover, the disease has also been called 4A or 5A syndrome 
depending if neurologic manifestations and amyotrophy are included. Due to its severity, the 
manifestation leading to the diagnosis is usually adrenal insufficiency which lead to hypoglycemic 
convulsions, growth delay and skin hyperpigmentation. Nonetheless, the earliest sign of this syndrome 
is actually alacrimia, which is almost invariably already existent at the moment of disease presentation 
2,3. In fact, the clinical diagnosis of TAS is usually made through the combination of 2 manifestations 
out of the classic Allgrove triad, although some authors claim that even incomplete presentations, 
especially the recognition of alacrimia alone, are highly suspicious for this syndrome 3–5. Once the 
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clinical manifestations have been carefully evaluated, genetic testing is important for final diagnosis. 
Moreover, symptoms, especially neurological disorders, may also evolve over time leading to the idea 
that this is a progressive disease.  
Alacrimia 
Among the three components of the common triad it has been reported that Alacrimia is the most 
prevalent first symptom attested in around 90-100% of the reported cases 6–9. Alacrimia is sometimes 
reported to be present from birth or noted within the first year of life 10,11. However, usually patients do 
not refer to the clinician for this specific symptom which is often reported only after direct questioning. 
The pathogenesis of alacrimia is probably related to a dysfunction of the autonomic nervous system in 
the lacrimal glands 2,12,13 and it is confirmed using the Schirmer’s test. This is performed using a filter 
paper strip that has to be positioned under both the lower eyelids of the patient while these are gently 
closed. The test takes 5 minutes, and after this time has lapsed, the moisture on these strips is 
evaluated: if it involves less than 10 mm the Schirmer’s test is positive, indicating a condition of 
reduced or absent tears. Since alacrimia as a first sign of TAS is so recurrent many authors suggest to 
always start diagnostic workup for TAS whenever it is present 2,14,15, while its absence almost rules out 
the condition 8. In particular, the study of the adrenal function is mandatory, because even the 
asymptomatic alterations could precede acute adrenal failure, and thus cortisol secretion should be 
assessed at once and every two years in this subset of patients 2. In order to treat this symptom, the 
patient is administered with artificial tears and lubricants to relief the dryness sensation, using viscous 
preparations for the more severe forms. If the discomfort is progressive, it could be necessary to use 
continuous-release ocular inserts or punctual occlusion. The treatment is important as untreated 
alacrimia may lead to keratopathy, keratoconjunctivitis sicca, corneal melt and ulceration 2,4. Thus, an 
annual ophthalmologic evaluation is recommended 12. Other findings related to this condition can be 
Pogliaghi et al, 2019
lacrimal gland atrophy, pupillary abnormalities (sluggish or tonic pupils), optic atrophy in adjunction to 
hypersensitivity to dilute miotics 16–18.  
Achalasia 
Esophageal achalasia of the cardia is found in almost 75-85% of TAS diagnoses 19–21 although a recent 
paper from Patt and coworkers reported a higher prevalence of 93% 8. Moreover, follow up studies of 
TAS patients suggest that the vast majority of affected subjects will develop achalasia, perhaps earlier 
in those presenting severe hormonal defects 3.  
Achalasia is described by two findings: loss of esophageal peristalsis and incomplete relaxation of the 
lower esophageal sphincter 22.  The age of onset of this feature usually ranges from 3 months to 16 
years 19,20. As suggested for alacrimia, also in children presenting with achalasia is indicated to 
investigate adrenal functionality as well as other signs and symptoms of the syndrome 2 . The clinical 
presentation of achalasia in these patients is vomiting, weight loss, difficulty to swallow and chronic 
coughing 23,24, which could precede the diagnosis of TAS of many years 15,23–27. 
 The method of diagnosing achalasia is manometry, but also timed barium meal esophagogram is quite 
sensitive for early diagnosis. Manometry is also used to evaluate the severity of the disease and the 
choices regarding the treatment 2,28.  
There is no consensus on first-line treatment of this condition since non-surgical therapy using 
pneumatic dilation is short-lasting, although inexpensive and effective, whereas 
esophagocardiomyotomy is more invasive but with long-term benefits 4,28.  
Adrenal Insufficiency 
Adrenal insufficiency is another of the most common symptoms which usually develops within 10 
years from birth 2,26 and only rarely remain undiagnosed until 50 years 29. As it may lead to sever 
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cause of death in unrecognized TAS patients 30. Usually, it is accompanied to skin hyperpigmentation, 
and its diagnosis is made according to the severity of the disorder. Overt adrenal insufficiency is 
diagnosed by clinical manifestation, low and high basal level of serum cortisol and plasma ACTH, 
respectively, and a peak serum cortisol level <18 µg/dL following intravenous (i.v.) injection of 250 µg/
m2 Synacthen (ACTH test).  On the other hand, subclinical adrenal insufficiency is defined as an 
asymptomatic disease with normal basal serum cortisol levels and sufficient cortisol response to ACTH 
test (peak cortisol <18 µg/dL, and <7 µg/absolute increase in cortisol levels), but with high basal 
plasma ACTH level. In patients with conflicting results, insulin-induced hypoglycemia test (ITT) 
should be considered 31,32. 
Moreover, it is noteworthy that the evaluation of adrenal functionality in TAS patients should not be 
limited to the glucocorticoid deficiency. In fact, in studies evaluating the function of the zona 
reticularis, an impairment, demonstrated by low DHEA-S levels, was found independently from the 
degree of glucocorticoid deficiency, suggesting a precocious failure of this zone 2,3. On the other hand, 
aldosterone deficiency is much rarer, with only few studies reporting alterations of electrolytes 
requiring mineral-corticoid supplementation 33,34. These different susceptibilities in the adrenal cortex, 
with a center-to-periphery gradient of damage, are not yet fully explained even if two hypothesis have 
been made: (i) a reduced production of reactive oxygen species during different hormones production, 
with less consequent oxidative stress 35, or (ii) the influence of cortical cell renewal that is known to be 
centripetal 3. So, if electrolytes disorders should be always assessed and confirmed with aldosterone 
and renin dosages in order to rule out the rare occurrence of mineralcorticoid deficiency, the evaluation 
of DHEA-S could represent, along with ACTH, a useful early assessment to detect precocious/initial 
adrenal failure. 
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The replacement therapy is always indicated in patients having a diagnosis of overt glucocorticoid 
deficiency, although some authors, evaluating the follow up of TAS patients, suggested a mere 
education to manage a treatment of stressful conditions in subclinical/compensated forms 3. It is 
important a strict follow up with a first evaluation at 3 months after diagnosis and then 2 time every 
year. The treatment of election in these patients is hydrocortisone, at the dosage of 10-15 mg/m2 every 
day, in three administrations. The treatment of mineral-corticoid deficiency using fludrocortisone 0.1 
mg/day, should be given only with a sure hormonal diagnosis 36.  
Adrenal functionality is recommended to be tested lifelong, as previously indicated, also in the 
presence of an initial normal result especially in the presence of alacrimia or achalasia.  
Neurological disorders 
TAS is characterized by an inconstant but progressive neurological impairment involving the central, 
peripheral, and autonomic nervous systems, which is the main prognostic factor of these patients 
(especially exacerbation of neuropathy and cognitive disorders) 3.  
The age at onset is variable and is usually late (even if it has been reported that can be the first manifest 
signs), ranging from 2 to 25 years 3,37–39. The most common neurological manifestations are autonomic 
dysfunctions involving pupillary muscles 10 and hyperreflexia (with a prevalence up to 65% of affected 
patients 2) which underlie an upper motor neuron neuropathy 40. Other neurological signs and 
symptoms are postural hypotension, hearth rate instability, sweating, impotence, ataxia, dysarthria, 
distal motor and sensory neuropathy, other disorders of movements and intellectual disability 6,10,25,37. 
Unfortunately, these aspects of the syndrome are hardly treatable and do not respond to glucocorticoid 
treatment even if physical therapy could help to cope with these alterations 4. In alternative a new 
possible approach might be represented by the use of N-acetylcysteine (NAC) as recently reported 41. 
Authors showed that NAC is capable of reducing levels of thiobarbituric acid reactive substances 
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(TBARS), an indicator of increased oxidative stress, in patients with TAS. They thus suggested that the 
long-term effect of antioxidant treatment should be evaluated to determine the real benefit in terms of 
precluding degeneration in TAS patients.   
Finally, mental retardation is the most common cognitive deficit and, although assumed to probably 
depend from recurrent hypoglycemia, it is reported also in patients without manifest adrenal 
insufficiency. Therefore, it might be considered a manifestation of the disease itself.  Moreover, 
similarly to other neurological manifestations of the disease, it seems to be progressive 4. 
Oral disorders and other clinical manifestations 
Among the other manifestations of the syndrome, hyposalivation which lead to xerostomia, is an 
important feature, as it could contribute premature tooth loss, oral infections and to dysphagia 4. It is 
confirmed using sialometry 2[2] and artificial saliva seems to be useful 4[4]. 
Palmoplantar hyperkeratosis is another manifestation found in almost half of the patients and could 
represent a suggesting diagnostic evidence in patients with TAS 2[2].  
A peculiar habitus with short stature, long narrow face, thin upper lip and no eyelashes may also be 
present, as well as osteoporosis, dyslipidemia and long QT syndrome have been described as well 42–44  
Molecular Genetics 
TAS is caused by mutations in the AAAS gene in most of the studied cases and it is inherited in an 
autosomal recessive pattern. The gene was first localized to 12q13 45,46 and was then further 
characterized by studies of linkage disequilibrium leading to the identification of its 16 exons and 
product 44,47.  The AAAS gene codifies for ALADIN, a 546 aa protein weighting 60 kDa. While the 
mRNA was found to be ubiquitously expressed in all tissues, the protein ALADIN was found to be 
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strongly expressed only in the pancreas, adrenal and pituitary gland 48. A splicing isoform of AAAS, 
called AAAS-v2, was also reported and detected in brain, liver, kidney, pancreas, thymus, testis and 
ovary. This isoform excludes the exon 6 in respect to AAAS-v1, the main isoform, and encodes for a 
513 aa protein with three WD repeats one less than AAAS-v149.  
ALADIN is a nucleoporin that localizes at the nuclear pore complex (NPC) on the cytoplasmatic side 
and is anchored by the nucleoporin NDC150,51. A study by Rabut and colleagues (2004) classified 
ALADIN as a “barely exchangeable” scaffold protein of the NPC with a very low dissociation rate and 
a high residence rate. ALADIN is part of the WD repeat family of proteins, having four WD repeats, 
that have been found to be involved in many different functions such as protein-protein interaction, 
RNA processing, cytoskeleton assembly, control of cell division, signal transduction and apoptosis 52. 
Immunohistochemical analysis showed that mutated or truncated ALADIN localizes to the cytoplasm 
rather than to the NPC. Indeed, Cronshaw and coworkers found that the essential residue necessary for 
nuclear pore localizations is located between amino acids 478 and 499 53. The group also noted that the 
c.43C>T AAAS mutation in exon 1 produced a protein that was still capable of causing the syndrome 
despite correctly localizing to the nuclear pore complex. The reason behind the pathogenicity of this 
apparently anomalous variant was later discovered by Krumbholz et al. which found that the c.43C>T 
mutation lead to an altered splicing event resulting in the decay of the incorrect mRNA or in a short 
ALADIN protein improperly localizing to the cytoplasm 54.  
While the exact function of the ALADIN protein remains mostly unclear, attempts have been made to 
clarify the pathogenetic mechanism of the different mutations reported, seemingly causing impaired 
nuclear import of DNA repair proteins and the intensification of oxidative stress status in the cell. 
Hirano and colleagues studying the mutant ALADIN I482S, found that mutated cells had impaired 
Aprataxin (APTX) and DNA ligase I nuclear import. ALADIN I482S fibroblasts were also shown to be 
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more susceptible to oxidative stress which, together with impaired import of DNA repair proteins, 
caused increased cell death and may explain the progressive nature of the disease. 23. 
The oxidative stress characteristic of the disease was further defined by the finding of Storr et al. that 
ALADIN is important for the nuclear uptake of Ferritin Heavy Chain 1 (FTH1), a protein that has a 
protective role against oxidative stress 55. Indeed, Kind and coworkers found an increase of 2.7-fold of 
reactive oxygen species levels in AAAS mutated fibroblast versus healthy ones with an increase in 
SOD enzymes of 1.2-fold and a slight decrease in Catalase expression by 0.7-fold 56. Further studies 
confirmed an increase of oxidative stress in H295R human adrenocortical tumor cells and SH-SY5Y 
human neuroblastoma cells after AAAS knockdown 25. Moreover, AAAS knockdown in the human 
adrenocortical cell line NCI-H295R1 induces a decreasing biosynthesis of precursor metabolites 
required for glucocorticoid and androgen production and a significantly impaired nuclear import of 
DNA ligase 1, aprataxin and ferritin heavy chain 1 35. 
ALADIN also interacts with PGRMC2, a protein belonging to the membrane-associated progesterone 
receptor (MAPR) group, capable, among other roles, to regulate the activity of CYP P450 cytochromes. 
This interaction, discovered with co-immunoprecipitation experiments by Juhlen and coworkers, could 
explain the adrenal atrophy encountered in TAS, as altered PGRMC2 localization may impact 
microsomal CYP P450 which are involved in steroidogenesis activity in adrenal cells 57. 
Of interest, it has also been found that ALADIN depletion impair the correct functioning of NuMa in 
the mitotic spindle formation process by altering the localization of Aurora A, a serine/threonine kinase 
involved in the regulation of NuMa localization by phosphorylation. This alteration was found to be 
less damaging than NuMa depletion, consistent with the relatively milder phenotype of TAS. Indeed, 
depletion of ALADIN causes a reduction but not elimination of the spindle focusing function of NuMa 
and Aurora A. As depletion of ALADIN is not enough to block cell division, the authors hypothesize 
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that ALADIN’s role in the regulation of Aurora A simply strengthen the spindle assembly in normal 
cells proposing that this role may be more significant in different types of tissue 58. A further insight on 
the role of ALADIN concerning cell division has been produced by Juhlen and colleagues, discovering 
that depletion of ALADIN in human adrenocortical cells and skin fibroblasts result in an accumulation 
of PGRMC1 in the cytosol. The mislocalization of this protein impedes its activity at the level of the 
mitotic spindle, thus impairing cell division by loss of stability of K-fibers. The group also found that 
PGRMC1 is regulated by Aurora A and PGRMC2 that are seemingly impaired in their function by 
alterations of ALADIN 59.  
Of note, in the first study to assay the effect of an AAAS mutation in the central nervous system, Bitetto 
and coworkers found that the c.464G>A mutation caused a reduction in the AAAS-v1 expression but 
an overexpression of AAAS-v2 in the patient’s fibroblast.  Consistently, ALADIN presence was 
reduced in the patient’s brain, cerebellum and spinal cord but remained normal in fibroblast where the 
expression of AAAS-v2 was upregulated 60.  
To date, 74 mutations in the AAAS gene causing TAS were reported in the literature; most of them are 
nonsense and frameshift, accounting for 56.8% of all mutation types, likely producing a truncated and 
non-fully functioning protein. Missense mutations account for 28.4% and splice-site mutations account 
for 14.8% (See Figure 1) 3,9,41,61–69,10,70–79,11,80–89,12,90–99,16,100–109,26,110–119,29,120–126,38,39. 
Mutations were found throughout the AAAS gene, suggesting no hotspots. However, Patt and 
coworkers  
found that some of the most recurring mutations exhibit a clustering in certain geographical areas, such 
as c.1432C>T and c.787T>C for Europe, c.771delG for China, c.43C>A and c.762delC for India and 
the very commonly reported splice-site mutation c.1331+1G>A for Africa and USA8. 
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Three deletions have also been reported as pathogenetic mechanisms causing TAS. The first is an Alu-
mediated rearrangement causing a 3.2 kb deletion implicating the 5’-flanking region, exon 1, intron 1 
and exon 2 of the AAAS gene, the second is the g.16166_17813delinTGAGGCCTGCTG homozygous 
indel mutation encompassing introns 7 to 10 of the AAAS gene, the third is the recently reported g.
53306793_53321761del homozygous deletion of the exon 7 of C12orf10 and all exons of the AAAS 
gene 61,97,127. Furthermore, a few heterozygous AAAS gene microdeletions implicating also the HOX 
gene clusters and neighboring genes have been reported causing psychomotor retardation and skeletal 
abnormalities but not causing TAS symptoms, despite being possible conductors for the syndrome if 
another disease-causing mutation were to occur 128–130. 
Next Generation Sequencing techniques applied to Triple-A Syndrome  
The majority of TAS cases were reported to be due to mutations of the AAAS gene, however a minority 
of cases (below 10%) presented with no clear underlying genetic cause.  
Recently, a Whole Exome Sequencing (WES) experiment has been performed by Kohler and 
colleagues on 13 patients affected by alacrimia, achalasia and intellectual disability but, interestingly, 
not by adrenal insufficiency, with no mutations in the AAAS gene. The group found mutations in the 
GMPPA gene, that produces a 420 aa protein called GMPPA (GDP-mannose pyrophosphorylase A). 
The function of this enzyme is not currently understood but the closest homolog GMPPB mutations are 
involved in glycosylation defects. The phenotype of these patients did not fully overlap with the TAS 
and so were diagnosed with AAMR (Alacrimia, Achalasia and Mental Retardation)131. A novel splice-
site variant mutation in the gene GMPPA was also discovered in a WES experiment by Gold and 
coworkers in two affected sisters from a consanguineous Lebanese family with TAS-like symptoms, 
but no alteration in the AAAS gene132. 
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Another WES experiment performed by Kohler et al. discovered a novel splice-site mutation in 
TRAPPC11 in two families with symptomatology overlapping that of TAS and not carrying mutation in 
AAAS and GMPPA genes. TRAPPC11 is a transport protein and was known to be involved in 
myopathy133. 
It should be then stressed that patients suffering from achalasia and alacrimia with suspected TAS but 
carrying no mutations in the AAAS gene should be prime candidates from WES to hopefully understand 
more extensively the molecular genetics signature of the Triple-A and TAS-like Syndromes. 
Triple-A Syndrome in-vitro and in-vivo models  
As previously showed, most of the studies featuring models were based on in vitro studies of 
adrenocortical cells and fibroblast cells and helped clarify some aspects of the TAS 23,25,35,55,56. A mouse 
model Aaas -/- has also been designed to hopefully recapitulate the disease in a more advanced model. 
Unfortunately, Huebner and coworkers demonstrated that the phenotype of Aaas -/- mice did not 
recapitulate the human TAS and are characterized by mild abnormal behavior and few neurological 
deficits. Female Aaas -/- mice were also found to be sterile134. 
Juhlen and colleagues attempted to study the role of oxidative stress regulation in Aaas KO and Aaas 
KO and heterozygous for superoxide dismutase 2 (Aaas KO/Sod2 Het mouse) that should have an 
increased susceptibility to oxidative stress, to generate a phenotype similar to that of the TAS. 
Interestingly, while this model failed to recapitulate any of the symptoms typical of the TAS, it showed 
that Aaas KO/ Sod2 Het mice were able to compensate for the additional oxidative stress by 
upregulating Nnt which in turns sustains high glutathione (GSH) levels. This compensatory mechanism 
partly explains why mice ALADIN-deficient lack the TAS syndrome phenotype and resemble WT 
mice135. 
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Conclusive remarks 
Given the rarity of the condition and the potentially detrimental adrenal insufficiency that is associated 
with TAS syndrome, with this review we aim to stress the importance of an early investigation of 
children presenting with alacrima, achalasia, or other cardinal symptoms of the syndrome. 
In fact, TAS is a heterogeneous disease that can have a more complex presentation than the classic triad 
of ACTH-resistant adrenal insufficiency, alacrimia and achalasia. Esophageal achalasia and adrenal 
insufficiency are the usual presenting manifestations. Nevertheless, alacrimia is the earliest and most 
consistent feature (although often overlooked by parents and clinicians) and many other clinical 
manifestations have been associated to the disease; thus, a more complex and comprehensive approach 
to this syndrome could facilitate an early diagnosis of the disease. Better awareness of the disease, 
followed by vigilant observation for the development of adrenal insufficiency, is warranted to improve 
survival rates.  
Different therapeutic options could be adopted for the efficient treatment of the cardinal signs of this 
syndrome and the efficacy of antioxidant treatment for the management of the progressive neurological 
degeneration showed in TAS patients is a promising therapeutic option that needs to be confirmed by 
further studies. 
When TAS is suspected, molecular genetic testing offers definite confirmation of diagnosis, early 
management as well genetic counseling and reproductive options for the family. 
Mutations in patients with TAS are distributed through all 16 exons of the gene. No hot-spots are 
identified in the gene and a comprehensive testing necessitates sequencing of the entire gene and 
especially intron-exon junction 54,118.To date, no clear-cut genotype-phenotype correlation could be 
deduced from the current literature, confirming the variable interfamilial and intrafamilial clinical 
presentation of TAS. The reason behind this high clinical heterogeneity is not known but it would be 
worth to investigate the potential involvement of other genes or mechanism in modulating the different 
aspects of the pathology. Moreover, some patients with TAS were reported with no mutations 
in AAAS gene, resulting elective candidates for WES analysis, that should be performed in order to 
identify new candidate genes and thus improving early diagnosis in all TAS and TAS-like 
patients132,133. 
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